Expert Opinion on Drug Safety

Article	Citations
Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis	62
Tackling antimicrobial resistance across sub-Saharan Africa: current challenges and implications for the future	49
Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety	40
Biologics in the treatment of pustular psoriasis	40
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients	39
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib	38
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients	36
Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis	36
Up-to-date expert opinion on the safety of recently developed antipsychotics	34
Gastrointestinal and cardiovascular adverse events associated with NSAIDs	34
Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines	33
A safety evaluation of aripiprazole in the treatment of schizophrenia	32
Long-term safety of ketamine and esketamine in treatment of depression	31
A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system	31
CGRP inhibitors for migraine prophylaxis: a safety review	28
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia	28
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database	28
Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects	28
Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion	27
Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review	26
Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis	25
Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases	25
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis	24
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence	24
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma	22

Safety of current therapies for onychomycosis	22
Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits	22
The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses	19
Current and emerging long-acting antipsychotics for the treatment of schizophrenia	19
Effects of the ABCB1 C3435T single nucleotide polymorphism on major adverse cardiovascular events in acute coronary syndrome or coronary artery disease patients undergoing percutaneous coronary	19
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge	19
Deprescribing in migraine	19
Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data	18
Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review	18
Selective serotonin reuptake inhibitors and the risk of congenital anomalies: a systematic review of current meta-analyses	18
Tafenoquine: a toxicity overview	17
Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review	17
Safety and efficacy of P2Y12inhibitor monotherapy in patients undergoing percutaneous coronary interventions	17
The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability	17
Gastroenterological safety of IL-17 inhibitors: a systematic literature review	16
The therapeutic potential of psilocybin: a systematic review	16
Long-term drug treatment in multiple sclerosis: safety success and concerns	16
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism	16
Safety and efficacy of pharmacologic agents used for rapid tranquilization of emergency department patients with acute agitation or excited delirium	15
Prevalence, characteristics, and reporting of adverse drug reactions in an Australian hospital: a retrospective review of hospital admissions due to adverse drug reactions	15
Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions	15
Current treatment options and safety considerations when treating adult-onset Still’s disease	15
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation	14
Safety and tolerability of spesolimab in patients with ulcerative colitis	14
Statin use and safety concerns: an overview of the past, present, and the future	14
Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections	14
Risks and benefits of reducing the number of drugs to treat HIV-1 infection	14
Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges	14
The risk of cardiovascular complications with current obesity drugs	14
Improving the safety of intravenous iron treatments for patients with chronic kidney disease	14
Antimicrobial resistance and the post antibiotic era: better late than never effort	14
Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study	13
An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles	13
Safety of dupilumab in patients with atopic dermatitis: expert opinion	13
A systematic review on pediatric medication errors by parents or caregivers at home	13
Current strategies for managing intestinal failure-associated liver disease	13
Online information discrepancies regarding safety of medicine use during pregnancy and lactation: an IMI ConcePTION study	13
Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review	13
Cilastatin as a protective agent against drug-induced nephrotoxicity: a literature review	12
Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system	12
The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis	12
A long-term open-label safety study of galcanezumab in Japanese patients with migraine	12
Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-a	11
Oral isotretinoin for acne: a complete overview	11
Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review	11
Safety of current recombinant human growth hormone treatments for adults with growth hormone deficiency and unmet needs	11
The safety of current pharmacotherapeutic strategies for osteosarcoma	11
The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy	11
Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids	11
OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation	10

Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry	10
Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness	10
The safety of JAK kinase inhibitors for the treatment of myelofibrosis	10
Expert opinion on sonidegib efficacy, safety and tolerability	10
Psychopharmacology of Williams syndrome: safety, tolerability, and effectiveness	10
Evaluating safety in hyaluronic acid lip injections	10
Long-term safety of approved biologics for ulcerative colitis	10
Safety and tolerability of preventive treatment options for chronic migraine	10
Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?	10
Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review	10
The effect of patient sex on the efficacy and safety of anticancer immunotherapy	10
Thalidomide: history, withdrawal, renaissance, and safety concerns	10
Safety evaluations of adalimumab for childhood chronic rheumatic diseases	10
Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients	10
Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization	10
Can ketamine be a safe option for treatment-resistant bipolar depression?	9
A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension	9
Persistent sexual dysfunction after SSRI withdrawal: a scoping review and presentation of 86 cases from the Netherlands	9
Nothing is perfect: the safety issues of integrase inhibitor regimens	9
Safety of topical interventions for the treatment of actinic keratosis	9
Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor	9
The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trials	9
Toward digital-based interventions for medication adherence and safety	9
Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs	9
Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability	9
Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer’s disease: a systematic review and meta-analysis	9
Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection	9
Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management	9
Safety of injectable semaglutide for type 2 diabetes	9
Concerns about the safety of anti-TNF agents when treating rheumatic diseases	9
Investigating the root cause of N-nitrosodimethylamine formation in metformin pharmaceutical products	9
Intravenous vs intravenous plus aerosolized colistin for treatment of ventilator-associated pneumonia – a matched case–control study in neonates	9
Systematic review and meta-analysis on the safety of dalbavancin	9
Anticholinergic medications and risk of dementia in older adults: Where are we now?	9
Is the lack of evidence in older adults with cancer compromising safety?	9
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom	9
Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice	8
Does the gut microbiome mediate antipsychotic-induced metabolic side effects in schizophrenia?	8
Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which?	8
Pharmacovigilance of anti-cancer medicines: opportunities and challenges	8
Safety considerations when managing gastro-esophageal reflux disease in infants	8
Safety of intranasal corticosteroids for allergic rhinitis in children	8
How can we manage the cardiac toxicity of immune checkpoint inhibitors?	8
A new paradigm in adverse drug reaction reporting: consolidating the evidence for an intervention to improve reporting	8
A safety review of approved intrathecal analgesics for chronic pain management	8
Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment	8
Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal	8
Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia	8
Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions	8
Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: focus on second-generation long acting injectable antipsychotics	8
Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis	8
Safety and tolerability evaluation of erenumab for the preventive treatment of migraine	8
Adverse drug reactions in elderly: a five-year review of spontaneous reports to the Portuguese pharmacovigilance system	8
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system	8
An umbrella review of systematic reviews on contributory factors to medication errors in health-care settings	8
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study	8
Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors	8
A review of hydroxyurea-related cutaneous adverse events	8
Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials	8
The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)	7
The ‘collateral side’ of mood stabilizers: safety and evidence-based strategies for managing side effects	7
A safety review of drugs used for the treatment of retinopathy of prematurity	7
Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents	7
Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides	7
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma	7
Safety implications of combining ACE inhibitors with thiazides for the treatment of hypertensive patients	7
A reappraisal of the role of fever in the occurrence of neurological sequelae following lithium intoxication: a systematic review	7
Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment	7
Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections	7
Safety of treatment options available for postoperative pain	7
Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer	7
Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions	7
A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine	7
Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system	7
Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy	6
Safety of current treatments for paroxysmal nocturnal hemoglobinuria	6
A review of the evidence on the risk of congenital malformations and neurodevelopmental disorders in association with antiseizure medications during pregnancy	6
An inter-professional student-run medication review programme. Reducing adverse drug reactions in a memory outpatient clinic: a controlled clinical trial	6
Cardiac adverse effects of antiseizure medications	6
Safety of treating acute liver injury and failure	6

Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)	6
Clinical profile of acute pancreatitis following treatment with protease inhibitors: a real-world analysis of post-marketing surveillance data	6
Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data	6
Effect of levosimendan on renal function in background of left ventricular dysfunction: a meta-analysis of randomized trials	6
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus	6
SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties	6
Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer	6
Safety of secukinumab for the treatment of active ankylosing spondylitis	6
Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome	6
Utilizing drug-target-event relationships to unveil safety patterns in pharmacovigilance	6
Introducing sexual dysfunction in mental care	6
Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice	6
Cardiovascular risks associated with protease inhibitors for the treatment of HIV	6
A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs	6
The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies	6
Drug-induced retroperitoneal fibrosis: a case/non-case study in the French PharmacoVigilance Database	6
Hepatotoxicity of FDA-approved small molecule kinase inhibitors	6
Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial	6
Safety considerations of current drug treatment strategies for nosocomial pneumonia	6
Immune-mediated inflammatory disease patients’ preferences in adverse drug reaction information regarding biologics	6